Skip to main content

Table 1 The basic clinical characteristics of HCC patients with CC (n = 35) and TT (n = 16) genotype

From: Use of proteomics to identify mechanisms of hepatocellular carcinoma with the CYP2D6*10 polymorphism and identification of ANGPTL6 as a new diagnostic and prognostic biomarker

Variables

CC n (%)

TT n (%)

P

Age (year)

  

0.091

 ≤ 50

13 (37.14)

10 (62.50)

 

 > 50

22 (62.86)

6 (37.50)

 

Gender

  

0.370

 Man

31 (88.57)

13 (81.25)

 

 Female

4 (11.43)

3 (18.75)

 

PLT (× 109/L)

  

0.022

 < 180

23 (65.71)

5 (37.50)

 

 ≥ 180

12 (34.29)

11 (62.50)

 

ALT (U/L)

  

0.360

 ≤ 40

23 (65.71)

8 (50.00

 

 > 40

12 (34.29)

8 (50.00)

 

AST (U/L)

  

0.179

 ≤ 40

18 (51.43)

5 (31.25)

 

 > 40

17 (48.57)

11 (68.75)

 

Albumin/globulin

  

0.020

 ≤ 1.5

21 (60.00)

4 (33.33)

 

 > 1.5

14 (40.00)

12 (66.67)

 

ALB (g/L)

  

0.355

 ≤ 70

18 (51.43)

6 (37.50)

 

 > 70

17 (48.57)

10 (62.50)

 

TBIL (μmol/L)

  

0.009

 ≤ 17

20 (57.14)

15 (93.75)

 

 > 17

15 (42.86)

1 (6.67)

 

DBIL (μmol/L)

  

0.043

 ≤ 7

18 (51.43)

13 (81.25)

 

 > 7

17 (48.57)

3 (18.75)

 

ALP (U/L)

  

0.242

 ≤ 130

27 (77.14)

15 (93.75)

 

 > 130

8 (22.86)

1 (6.67)

 

AFP (ng/mL)

  

0.246

 ≤ 300

17 (48.57)

5 (31.25)

 

 > 300

18 (51.43)

11 (68.75)

 

PT (s)

  

0.043

 ≤ 14

26 (74.29)

16 (100.00)

 

 > 14

9 (25.71)

0 (0)

 
  1. P values were calculated from two‐side chi‐square test
  2. AFP: alpha-fetoprotein; ALB: albumin; ALT: alanine amino transferase; ALP: alkaline phosphatase; AST: Aspartate amino transferase; DBIL: direct bilirubin; PLT: platelet; PT: prothrombin time; TBIL: total bilirubin